The role of toxicoproteomics in assessing organ specific toxicity.

B. Alex Merrick, Frank Witzmann

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims of this chapter on the role of toxicoproteomics in assessing organ-specific toxicity are to define the field of toxicoproteomics, describe its development among global technologies, and show potential uses in experimental toxicological research, preclinical testing and mechanistic biological research. Disciplines within proteomics deployed in preclinical research are described as Tier I analysis, involving global protein mapping and protein profiling for differential expression, and Tier II proteomic analysis, including global methods for description of function, structure, interactions and post-translational modification of proteins. Proteomic platforms used in toxicoproteomics research are briefly reviewed. Preclinical toxicoproteomic studies with model liver and kidney toxicants are critically assessed for their contributions toward understanding pathophysiology and in biomarker discovery. Toxicoproteomics research conducted in other organs and tissues are briefly discussed as well. The final section suggests several key developments involving new approaches and research focus areas for the field of toxicoproteomics as a new tool for toxicological pathology.

Original languageEnglish (US)
Pages (from-to)367-400
Number of pages34
JournalEXS
Volume99
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Research
Proteomics
Toxicology
Post Translational Protein Processing
Proteins
Biomarkers
Pathology
Technology
Kidney
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The role of toxicoproteomics in assessing organ specific toxicity. / Merrick, B. Alex; Witzmann, Frank.

In: EXS, Vol. 99, 2009, p. 367-400.

Research output: Contribution to journalArticle

@article{5c40cd2065824e809cccb81c94d56e35,
title = "The role of toxicoproteomics in assessing organ specific toxicity.",
abstract = "Aims of this chapter on the role of toxicoproteomics in assessing organ-specific toxicity are to define the field of toxicoproteomics, describe its development among global technologies, and show potential uses in experimental toxicological research, preclinical testing and mechanistic biological research. Disciplines within proteomics deployed in preclinical research are described as Tier I analysis, involving global protein mapping and protein profiling for differential expression, and Tier II proteomic analysis, including global methods for description of function, structure, interactions and post-translational modification of proteins. Proteomic platforms used in toxicoproteomics research are briefly reviewed. Preclinical toxicoproteomic studies with model liver and kidney toxicants are critically assessed for their contributions toward understanding pathophysiology and in biomarker discovery. Toxicoproteomics research conducted in other organs and tissues are briefly discussed as well. The final section suggests several key developments involving new approaches and research focus areas for the field of toxicoproteomics as a new tool for toxicological pathology.",
author = "Merrick, {B. Alex} and Frank Witzmann",
year = "2009",
doi = "10.1007/978-3-7643-8336-7_13",
language = "English (US)",
volume = "99",
pages = "367--400",
journal = "Experientia. Supplementum",
issn = "1023-294X",
publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - The role of toxicoproteomics in assessing organ specific toxicity.

AU - Merrick, B. Alex

AU - Witzmann, Frank

PY - 2009

Y1 - 2009

N2 - Aims of this chapter on the role of toxicoproteomics in assessing organ-specific toxicity are to define the field of toxicoproteomics, describe its development among global technologies, and show potential uses in experimental toxicological research, preclinical testing and mechanistic biological research. Disciplines within proteomics deployed in preclinical research are described as Tier I analysis, involving global protein mapping and protein profiling for differential expression, and Tier II proteomic analysis, including global methods for description of function, structure, interactions and post-translational modification of proteins. Proteomic platforms used in toxicoproteomics research are briefly reviewed. Preclinical toxicoproteomic studies with model liver and kidney toxicants are critically assessed for their contributions toward understanding pathophysiology and in biomarker discovery. Toxicoproteomics research conducted in other organs and tissues are briefly discussed as well. The final section suggests several key developments involving new approaches and research focus areas for the field of toxicoproteomics as a new tool for toxicological pathology.

AB - Aims of this chapter on the role of toxicoproteomics in assessing organ-specific toxicity are to define the field of toxicoproteomics, describe its development among global technologies, and show potential uses in experimental toxicological research, preclinical testing and mechanistic biological research. Disciplines within proteomics deployed in preclinical research are described as Tier I analysis, involving global protein mapping and protein profiling for differential expression, and Tier II proteomic analysis, including global methods for description of function, structure, interactions and post-translational modification of proteins. Proteomic platforms used in toxicoproteomics research are briefly reviewed. Preclinical toxicoproteomic studies with model liver and kidney toxicants are critically assessed for their contributions toward understanding pathophysiology and in biomarker discovery. Toxicoproteomics research conducted in other organs and tissues are briefly discussed as well. The final section suggests several key developments involving new approaches and research focus areas for the field of toxicoproteomics as a new tool for toxicological pathology.

UR - http://www.scopus.com/inward/record.url?scp=63249128015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249128015&partnerID=8YFLogxK

U2 - 10.1007/978-3-7643-8336-7_13

DO - 10.1007/978-3-7643-8336-7_13

M3 - Article

VL - 99

SP - 367

EP - 400

JO - Experientia. Supplementum

JF - Experientia. Supplementum

SN - 1023-294X

ER -